#VisualAbstract: Reduced-Dose was Not Non-Inferior to Full-Dose Direct Oral Anticoagulants in Venous Thromboembolism Patients

Click here to read this study in the Lancet.

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

Apixaban reduces bleeding risk versus rivaroxaban in acute venous thromboembolism

#VisualAbstract: Reduced-Dose was Not Non-Inferior to Full-Dose Direct Oral Anticoagulants in Venous Thromboembolism Patients

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

Apixaban reduces bleeding risk versus rivaroxaban in acute venous thromboembolism

2 Minute Medicine Rewind March 10, 2025

Differential optimal follicle sizes for ovulatory dysfunction and unexplained infertility

RelatedReports

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

Apixaban reduces bleeding risk versus rivaroxaban in acute venous thromboembolism

Left atrial appendage closure is safe and effective in atrial fibrillation

Differential optimal follicle sizes for ovulatory dysfunction and unexplained infertility

Endometriosis and Uterine Fibroids Associated with a Greater Risk of Mortality due to Gynecologic Cancers

Infigratinib shows promising efficacy and tolerability in pediatric achondroplasia

Recent Reports